- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Sebaceous Gland Carcinoma (SGC)
Sebaceous Gland Carcinoma (SGC) most commonly develops in the eyelids, but it may also occur in the head, neck, and trunk regions, which are abundant in sebaceous glands. For the diagnostic and therapeutic of sebaceous gland carcinomas, Protheragen provides fully integrated solutions.
Sebaceous gland carcinoma (SGC) is iniost radial/elliptic benign skin tumor in origin clearn a and usually developes in eye-lids region. Much of this tumor is clinically challenging due to the fact that it is often local recurs and metastates in malignancy therefore the prognosis remains gravely unfavorable. Sebaceous carcinoma has been more commonly reported recently, particularly in elderly Caucasian and male men. Thus, there is an increasing need to understand the pathogenesis of SGC and develop appropriate diagnostic and therapeutic approaches.
Fig.1 Histopathological analysis of sebaceous gland carcinoma. (Gall R., et al., 2023)
Molecular Diagnostics
The next generation sequencing (NGS) technology has made it easier to detect actionable alterations in the SGC profile which intellectually shed light on possible therapeutic strategies. For example, mutations are frequently found in TP53 and RB1 in periocular SGC, while extraocular SGC is often found with mutations in PIK3CA and PTEN.
Immunohistochemistry
EMA, adipophilin, and androgen receptor are typical markers for distinguishing SGC from other malignancies such as squamous cell carcinoma and basal cell carcinoma. IHC can detect molecular chaperones too, like XIAP and BAG3, which are overexpressed in SGC and aid in the tumor's survival and proliferation.
Epigenetic Markers
DNA methylation and histone modulation, among other types of epigenetic alterations, are now regarded as potentially useful diagnostic markers for SGC. For example, the E-cadherin gene is often SGC associated with promoter region methylation which results in absent E-cadherin expression. Thus, this epigenetic alteration indicates a certain stage of the disease.
MicroRNA Profiling
Pioneering efforts in miRNA profiling have uncovered the differential expression of several miRNAs including members of the miRNA-200 family in SGC. Due to their role in tumor progression and metastasis, these miRNAs could potentially act as diagnostic markers and therapeutic targets.
Our expertise in molecular diagnostics includes next-generation sequencing, immunohistochemistry, and miRNA profiling, providing robust tools for early detection and accurate diagnosis of SGC. Additionally, our therapeutic development services encompass neoadjuvant chemotherapy, targeted therapies, immunotherapy, and epigenetic modifiers, providing a multifaceted therapeutic development solution for this challenging malignancy.
Protheragen understands that each project is unique and requires a tailored approach. Our customized services are designed to meet the specific needs of our clients, providing flexible and innovative solutions for the development of diagnostics and therapeutics for sebaceous gland carcinoma. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.